Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
As computational methods continue to advance, we can expect an acceleration in the discovery and development of novel treatments for complex diseases.
FEV, Forced Expiratory Volume
GLP-1 encourages your pancreas to release insulin, which lowers the amount of glucose (a type of sugar) in your blood
Since the injection only needs to be taken once per week, it has been accepted well by patients who need long-term treatment for metabolic disorders
Over time, however, the treatment effect of a marginal 30-week regimen dissipated